Blood protein profile may forecast Triple-Negative breast cancer relapse
NCT ID NCT04438681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a set of proteins in the blood can predict if triple-negative breast cancer will come back after treatment. Researchers will follow 90 women and test their blood at several time points. The goal is to find a simple way to identify patients who need closer monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors predict which triple-negative breast cancer patients are at higher risk of cancer returning.
- What could go wrong
- This is an observational study, not a treatment trial. The protein profile may not prove accurate enough for routine use, and results may not change patient outcomes directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Jean PERRIN
Clermont-Ferrand, 63011, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?